ARGX · Argenx SE
AI read · Good for ARGX
The AI's read
Argenx reported positive topline Phase 3 ALKIVIA results for efgartigimod and the stock jumped roughly 12% premarket. The trial hit its primary endpoint with a 15.4-point TIS improvement and p=0.0011. The market has already moved about +8.1% since the announcement, so some upside is priced in. Still, the data are fresh and show early, sustained benefit across core measures. We lean bullish because a clean Phase 3, durable effect, and tolerable safety create a clear commercial and label-expansion path. Main risks are the smaller DM subgroup missing statistical significance and the usual post-readout data, regulatory, and reimbursement uncertainty.